3 Branded Pharmaceuticals Maker, Stainless Steel Pipes Maker and Abrasives Maker Stocks With a Strong Future Roadmap: JB Chemicals and Pharmaceuticals, Ratnamani Metals and Tubes and Grindwell Norton
- November 6, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
JB Chemicals and Pharmaceuticals, Ratnamani Metals and Tubes and Grindwell Norton: ROE of 11.7% to 17.1% and FY22 to FY26 revenue CAGR of 9.8% to 14.3%. Prices as of 5 Nov 2026.
Quick Answer
The three pharma, steel pipe and abrasive stocks to watch are JB Chemicals and Pharmaceuticals, Ratnamani Metals and Tubes and Grindwell Norton. Their return on equity ranges from 11.7% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.8% to 14.3%. JB Chemicals and Pharmaceuticals leads on both return on equity at 17.1% and revenue growth at 14.3% a year. Prices are based on the 5 November 2026 close, and this article is educational, not investment advice.
Pharma, steel pipe and abrasive stocks bring together companies with a visible plan for the years ahead. JB Chemicals and Pharmaceuticals, Ratnamani Metals and Tubes and Grindwell Norton cover a branded pharmaceuticals maker, a stainless steel pipes maker and an abrasives maker.
This list covers three pharma, steel pipe and abrasive stocks with complete current figures: JB Chemicals and Pharmaceuticals, Ratnamani Metals and Tubes and Grindwell Norton. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma, Steel Pipe and Abrasive Stocks?
Pharma, steel pipe and abrasive stocks are listed companies that make branded medicines and contract pharma products, produce stainless steel and carbon steel pipes for process industries, and manufacture abrasives, ceramics and refractories. Their earnings depend on prescription demand, plant investment and industrial output.
Pharma, Steel Pipe and Abrasive Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| JB Chemicals and Pharmaceuticals | 2,408.9 | 38,731 | 54.6 | 35.8 | 17.1 | 0.00 |
| Ratnamani Metals and Tubes | 2,454.1 | 17,569 | 34.2 | 44.4 | 11.7 | 0.08 |
| Grindwell Norton | 1,929.8 | 20,188 | 46.1 | 44.4 | 16.4 | 0.02 |
On valuation, Ratnamani Metals and Tubes trades at a P/E below the industry P/E, while JB Chemicals and Pharmaceuticals and Grindwell Norton trade above it, which reflects the growth the market already expects. Readers comparing pharma, steel pipe and abrasive stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pharma, Steel Pipe and Abrasive Stocks Have a Strong Roadmap in India?
Pharma, steel pipe and abrasive stocks have a strong roadmap in India because growing demand for chronic therapy medicines, rising investment in oil, gas and power projects and steady factory output keep widening the market for these companies.
- Pharma. Branded medicines reach more doctors and patients.
- Steel pipes. Process plants need high grade piping.
- Abrasives. Factories use grinding products daily.
Why JB Chemicals and Pharmaceuticals Features Among These Pharma, Steel Pipe and Abrasive Stocks
Among the pharma, steel pipe and abrasive stocks on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.
The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8.
Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.
Roadmap: The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.
What to watch: Monitor the growth of key domestic brands and the order flow in contract manufacturing.
Why Ratnamani Metals and Tubes Features Among These Pharma, Steel Pipe and Abrasive Stocks
Among the medicine, tube and industrial grinding shares on this list, Ratnamani Metals and Tubes makes stainless steel and carbon steel pipes and tubes for oil and gas, power, chemicals, fertilisers and nuclear applications, selling in India and overseas.
Revenue rose from Rs 3,176 crore in FY22 to Rs 4,616 crore in FY26, a compound annual growth rate of 9.8%. Net profit grew from Rs 323 crore in FY22 to Rs 534 crore in FY26, which works out to a compound annual growth rate of 13.4%.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 17,569 crore. The stock trades at a P/E of 34.2, below the industry P/E of 44.4.
Roadmap: The company is a specialist in demanding tube applications and holds a strong order book across energy and process industries. Capacity additions in welded pipes and a growing export presence extend its reach.
What to watch: Check the size of the order book and its execution through the year.
Why Grindwell Norton Features Among These Pharma, Steel Pipe and Abrasive Stocks
Among the three companies on this list, Grindwell Norton, a Saint-Gobain group company, makes abrasives, ceramics and plastics products, including grinding wheels, coated abrasives and silicon carbide.
In the June 2026 quarter, revenue grew 13.8% year on year to Rs 828 crore, while net profit rose 22.1% to Rs 115 crore. Revenue rose from Rs 2,066 crore in FY22 to Rs 3,168 crore in FY26, a compound annual growth rate of 11.3%.
Net profit grew from Rs 295 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 9.0%. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 20,188 crore. The stock trades at a P/E of 46.1, above the industry P/E of 44.4.
Roadmap: Demand from automobiles, steel, infrastructure and general manufacturing supports its core abrasives range, while ceramics and plastics offer higher-value niches. The group’s technology support and a debt-free balance sheet allow it to add capacity at its own pace.
What to watch: Keep tabs on industrial activity and input costs for raw materials such as silicon carbide.
JB Chemicals and Pharmaceuticals vs Ratnamani Metals and Tubes vs Grindwell Norton on Key Financials
The table below sets the three pharma, steel pipe and abrasive stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| JB Chemicals and Pharmaceuticals | 2,463 | 4,208 | 14.3% | 709 | 16.9% |
| Ratnamani Metals and Tubes | 3,176 | 4,616 | 9.8% | 534 | 11.6% |
| Grindwell Norton | 2,066 | 3,168 | 11.3% | 417 | 13.2% |
JB Chemicals and Pharmaceuticals posts the highest return on equity in this group at 17.1%. Ratnamani Metals and Tubes has the largest FY26 revenue at Rs 4,616 crore, and JB Chemicals and Pharmaceuticals shows the fastest revenue growth with a 14.3% compound annual rate. A useful habit with pharma, steel pipe and abrasive stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Pharma, Steel Pipe and Abrasive Stocks
Every theme carries risks that deserve a check before any decision. For these pharma, steel pipe and abrasive stocks, the main points are: Long-term medicine, tube and industrial grinding shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Capex cycles. Customer spending on plants and projects can vary.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma, steel pipe and abrasive stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma, Steel Pipe and Abrasive Stocks
Pharma, steel pipe and abrasive stocks suit investors who prefer to study business strength before price moves. JB Chemicals and Pharmaceuticals, Ratnamani Metals and Tubes and Grindwell Norton each have a clear plan to grow. Based on the 5 November 2026 close, JB Chemicals and Pharmaceuticals trades at Rs 2,408.9, Ratnamani Metals and Tubes at Rs 2,454.1 and Grindwell Norton at Rs 1,929.8. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma, steel pipe and abrasive stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma, steel pipe and abrasive stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma, steel pipe and abrasive stocks?
Ans. Pharma, steel pipe and abrasive stocks are listed companies that make branded medicines and contract pharma products, produce stainless steel and carbon steel pipes for process industries, and manufacture abrasives, ceramics and refractories. Their earnings depend on prescription demand, plant investment and industrial output. This list looks at three of them, JB Chemicals and Pharmaceuticals, Ratnamani Metals and Tubes and Grindwell Norton, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.
Which pharma, steel pipe and abrasive stocks are covered in this list?
Ans. This list covers JB Chemicals and Pharmaceuticals, Ratnamani Metals and Tubes and Grindwell Norton. Based on the 5 November 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Ratnamani Metals and Tubes at Rs 2,454.1 and Grindwell Norton at Rs 1,929.8. Their return on equity ranges from 11.7% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.8% to 14.3%.
Why do pharma, steel pipe and abrasive stocks have a strong future roadmap in India?
Ans. Pharma, steel pipe and abrasive stocks have a strong roadmap in India because growing demand for chronic therapy medicines, rising investment in oil, gas and power projects and steady factory output keep widening the market for these companies. The main drivers are as follows. Pharma. Branded medicines reach more doctors and patients. Steel pipes. Process plants need high grade piping. Abrasives. Factories use grinding products daily. Together these factors give the companies on this list a visible path for growth over the coming years.
How has JB Chemicals and Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.
How has Ratnamani Metals and Tubes performed financially?
Ans. Revenue rose from Rs 3,176 crore in FY22 to Rs 4,616 crore in FY26, a compound annual growth rate of 9.8%. Net profit grew from Rs 323 crore in FY22 to Rs 534 crore in FY26, which works out to a compound annual growth rate of 13.4%. The company has a return on equity of 11.7%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 17,569 crore. The stock trades at a P/E of 34.2, below the industry P/E of 44.4. Looking ahead, the company is a specialist in demanding tube applications and holds a strong order book across energy and process industries. Capacity additions in welded pipes and a growing export presence extend its reach.
How has Grindwell Norton performed financially?
Ans. Revenue rose from Rs 2,066 crore in FY22 to Rs 3,168 crore in FY26, a compound annual growth rate of 11.3%. Net profit grew from Rs 295 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 9.0%. In the June 2026 quarter, revenue grew 13.8% year on year to Rs 828 crore, while net profit rose 22.1% to Rs 115 crore. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 20,188 crore. The stock trades at a P/E of 46.1, above the industry P/E of 44.4. Looking ahead, demand from automobiles, steel, infrastructure and general manufacturing supports its core abrasives range, while ceramics and plastics offer higher-value niches. The group’s technology support and a debt-free balance sheet allow it to add capacity at its own pace.
What risks should investors check before buying pharma, steel pipe and abrasive stocks?
Ans. Investors should check a few risks before buying pharma, steel pipe and abrasive stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Capex cycles. Customer spending on plants and projects can vary. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma, steel pipe and abrasive stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.